Results 1 to 10 of about 82,161 (336)
Application of sirolimus in an infant presenting with a life-threatening lymphatic malformation of the head and neck: a case report [PDF]
Frontiers in PediatricsExtensive lymphatic malformations in the head and neck region pose a significant risk due to potential airway compression, and conventional treatment modalities have proven largely ineffective.
Shuying Yu, Xiaowen Guo
doaj +2 more sources
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. [PDF]
New England Journal of Medicine, 2002 BACKGROUND The need for repeated treatment of restenosis of a treated vessel remains the main limitation of percutaneous coronary revascularization.
M. Morice +11 more
semanticscholar +2 more sources
Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review
Acta Dermato-Venereologica, 2019 Vascular anomalies (VAs) may be associated with significant morbidity and mortality. The aim of this study was to evaluate the efficacy and safety of sirolimus (rapamycin) in the treatment of children and young adults with complicated VAs.
Shira Sandbank +4 more
doaj +2 more sources
A Tablet Matrix with Hibiscus rosa Sinensis Leave Mucilage for Effective Treatment of Rare Lymphangioleiomyomatosis Using Sirolimus [PDF]
Trends in Pharmaceutical Sciences, 2022 Using a blend of herbal and synthetic polymers, the authors aim to extend the release of Sirolimus from the tablets. Sirolimus was used as a model drug, Hydroxy Propyl Methyl Cellulose was used as a synthetic polymer, and mucilage from Hibiscus rosa ...
Hindustan Abdul Ahad +5 more
doaj +1 more source
Frontiers in Pharmacology, 2023 The mTOR inhibitor sirolimus is prescribed to treat children with varying diseases, ranging from vascular anomalies to sporadic lymphangioleiomyomatosis to transplantation (solid organ or hematopoietic cell).
Guofang Shen +7 more
doaj +1 more source
JCI Insight, 2023 BACKGROUND Slow-flow vascular malformations frequently harbor activating mutations in the PI3K/AKT/mTOR cascade. Phase II trials pinpointed sirolimus effectiveness as a drug therapy.
Emmanuel Seront +16 more
semanticscholar +1 more source
Blood, 2022 The Kasabach-Merritt phenomenon (KMP) in kaposiform hemangioendothelioma (KHE) is characterized by life-threatening thrombocytopenia and consumptive coagulopathy. This study compared the efficacy and safety of sirolimus plus prednisolone versus sirolimus
Yi Ji +13 more
semanticscholar +1 more source
Efficacy of sirolimus in children with lymphatic malformations of the head and neck
European Archives of Oto-Rhino-Laryngology, 2022 Children with extensive lymphatic malformations of the head and neck often suffer from functional impairment and aesthetic deformity which significantly affect the quality of life and may be life-threatening. Treatment with sirolimus has the potential to
S. Wiegand, A. Dietz, G. Wichmann
semanticscholar +1 more source
Sirolimus for epileptic seizures associated with focal cortical dysplasia type II
Annals of Clinical and Translational Neurology, 2022 To determine whether sirolimus, a mechanistic target of rapamycin (mTOR) inhibitor, reduces epileptic seizures associated with focal cortical dysplasia (FCD) type II.
Mitsuhiro Kato +11 more
semanticscholar +1 more source
Sirolimus as a second-line treatment for Graves’ orbitopathy
Journal of Endocrinological Investigation, 2022 A beneficial effect of sirolimus in Graves’ orbitopathy (GO) was reported, suggesting a possible use in clinical practice. We conducted an observational, single-centre, no-profit, clinical study to investigate the efficacy of sirolimus as a second-line ...
G. Lanzolla +8 more
semanticscholar +1 more source